1Taltz [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3Pariser D, Heffernan M, Dennehy EB, et al. The effects of age, gender, weight, age at onset, psoriasis severity, nail involvement, and presence of psoriatic arthritis at baseline on the efficacy of ixekizumab in patients with moderate-to-severe psoriasis. Poster presented at: 75th Annual Meeting of the American Congress of Dermatology; March 3-7, 2017; Orlando, FL.